drugset / Trial / NCT02097277
A Study to Evaluate BMS-986036 in Obese Adults With Type-2 Diabetes
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to assess the potential of BMS-986036 for treatment obese adults with type-2 diabetes.
Timeline
- Start
- 2014-04-15
- Primary completion
- 2015-09-22
- Completion
- 2016-05-17
Outcome
Missed primary endpoint
paper There were no significant effects of pegbelfermin versus placebo on HbA1c. PMID 30520566 ↗
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pegbelfermin | Protein / enzyme biologic | 1 mg | Subcutaneous |
| Subject | Pegbelfermin | Protein / enzyme biologic | 5 mg | Subcutaneous |
| Subject | Pegbelfermin | Protein / enzyme biologic | 20 mg | Subcutaneous |